menu
    • menu
    [{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Recombinant anti-coronavirus 19 hyperimmune gammaglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Grifols","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Grifols"},{"orgOrder":0,"company":"GigaGen","sponsor":"ProteoNic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ ProteoNic","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ ProteoNic"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Recombinant Human Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"GigaGen \/ Department of Defense"},{"orgOrder":0,"company":"GigaGen","sponsor":"ProteoNic","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ GigaGen"},{"orgOrder":0,"company":"GigaGen","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ National Cancer Institute"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GIGA-2339","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Recombinant Polyclonal Antibody Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GigaGen","amount2":0.14000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GigaGen \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"GigaGen \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals by GigaGen

    Menu

    GigaGen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Polyclonal Antibody Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : BARDA

                            Deal Size : $135.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            GigaGen Wins U.S. BARDA Contract for Polyclonal Antibody Therapy Development

                            Details : The funding will be used to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and an additional biothreat.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : Recombinant Polyclonal Antibody Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : BARDA

                            Deal Size : $135.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-2339

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GigaGen Receives FDA IND Clearance for Phase 1 Trial of GIGA-2339 for HBV

                            Details : GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection

                            Brand Name : GIGA-2339

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 31, 2024

                            Lead Product(s) : GIGA-2339

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GigaGen Doses First Patient In Phase 1 Trial Of GIGA-564 For Solid Tumors

                            Details : GIGA-564 is a differentiated fully human monoclonal anti-CTLA-4 antibody, which is currently being evaluated for the treatment of advanced solid tumors.

                            Brand Name : GIGA-564

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 20, 2024

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tu...

                            Details : GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action, led to reduced colon and skin inflammation.

                            Brand Name : GIGA-564

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

                            Details : The agreement aims to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564, a fully human monoclonal antibody, distinguishes itself from currently available anti-CTLA-4 drugs.

                            Brand Name : GIGA-564

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 28, 2023

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Polyclonal Antibody

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Recipient : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic™ Technology

                            Details : Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 01, 2022

                            Lead Product(s) : Recombinant Polyclonal Antibody

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Recipient : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Polyclonal Antibody

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for Hig...

                            Details : As part of this award, GigaGen will demonstrate its platform’s capabilities by producing recombinant human hyperimmune products that target DOD-priority pathogens, including a recombinant polyclonal antibody drug designed to neutralize botulinum neurot...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 15, 2022

                            Lead Product(s) : Recombinant Human Polyclonal Antibody

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-2050

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its N...

                            Details : GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of t...

                            Brand Name : GIGA-2050

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 28, 2022

                            Lead Product(s) : GIGA-2050

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Dr...

                            Details : GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action, led to reduced colon and skin inflammation.

                            Brand Name : GIGA-564

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : GIGA-564

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GigaGen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GIGA-2050

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- an...

                            Details : Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs including GIGA-2050.

                            Brand Name : GIGA-2050

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 30, 2021

                            Lead Product(s) : GIGA-2050

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth